Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases

Clemente, Daniel; Udaondo, Clara; Arocena, Jaime de Inocencio; Nieto, Juan Carlos; Río, Pilar Galán del; García-Fernández, Antía; Palomo, J. Arroyo; Bachiller‐Corral, Javier; Robledillo, Juan Carlos López; Longo, Claudia Millán; León, Leticia; Abásolo, Lydia; Boteanu, Alina

doi:10.1186/s12969-021-00648-5

Cited by 20 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most cases were mild, with one third of asymptomatic cases. In line with our findings, their results suggest that associated comorbidities and treatment with glucocorticoids increase the risk of hospital admission [ 12 ]. Results from the national paediatric rheumatology database in Germany show similar results, with 76 cases of COVID-19 in children with rheumatic diseases, with mild outcome and good recovery in the majority of cases, and no relevant impact on disease activity [ 13 ].…”

Section: Discussionsupporting

confidence: 91%

Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases—cross-sectional study from a reference centre in Spain

et al. 2022

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 infections in children are frequently asymptomatic or mild and can go unnoticed. This study aimed to describe the seroprevalence and clinical course of SARS-CoV-2 in a cohort of children with rheumatic diseases in a real-life setting and assess possible risk factors. A cross-sectional study was performed in a paediatric rheumatology unit (September 2020 to February 2021). At inclusion, a specific questionnaire was completed and SARS-CoV-2 serology was performed. Demographics, treatment and disease activity of patients with and without laboratory-confirmed SARS-CoV-2 infection were compared. A total of 105 children were included. SARS-CoV-2 infection was demonstrated in 27 patients (25.7%). The mean age was 11.8 years, and most patients were females (72.4%). The most frequent underlying condition was juvenile idiopathic arthritis (70.3%; 19/27). Patients received immunosuppressive treatment in 78% of cases (21/27). Overall, 44.4% (12/27) of infected patients were asymptomatic. A total of 66.7% (18/27) of patients did not require medical assistance. Three patients required hospital admission because of COVID-19. Children with confirmed SARS-CoV-2 infection were less frequently in remission (52% vs 72%; p 0.014). Moderate disease activity and treatment with oral corticosteroids were associated with higher risk for SARS-CoV-2 (OR 5.05; CI 95%: 1.56–16.3 and OR 4.2; CI 95%: 1.26–13.9, respectively). In a cohort of Spanish paediatric patients with rheumatic diseases, clinical course of COVID-19 was mild, with more than one third of asymptomatic cases. Higher disease activity and oral corticosteroids appear to be risk factors for SARS-CoV-2 infection. Key Points • We aimed to investigate the seroprevalence of SARS-CoV-2 infection in a cohort of Spanish paediatric patients with RD, testing both symptomatic and asymptomatic patients. We also compared treatment and disease activity of patients with and without laboratory-confirmed SARS-CoV-2 infection. • In our cohort of 105 paediatric patients with rheumatic diseases, the clinical course of COVID-19 was mild and 44% of cases were asymptomatic. Three cases required hospital admission with no complications. Seroprevalence was 20%. • No association was found between disease activity or treatment with corticosteroids and symptomatic or asymptomatic infection. Higher disease activity and treatment with oral corticosteroids appeared to be risk factors for laboratory-confirmed SARS-CoV-2 infection.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases—cross-sectional study from a reference centre in Spain

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two studies in pediatric SLE reported favorable outcomes, with a prevalence of 2.6% and none requiring hospitalization in the study from the USA [ 29 ], whereas the Spanish study reported eight cases with one requiring hospitalization [ 30 ].…”

Section: Features Of Covid-19 In Patients With Sle and Effects Of Drugsmentioning

confidence: 99%

Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management

et al. 2022

View full text Add to dashboard Cite

Patients with systemic lupus erythematosus (SLE) form a vulnerable group in terms of the impact of the COVID-19 pandemic on disease management. We conducted this overview by searches through Medline/PubMed, Scopus, and the Directory of Open Access Journals (DOAJ). The prevalence and severity of COVID-19, efficacy of COVID-19 vaccination, impact on the management of SLE, and the attitudes of SLE patients to COVID-19 and vaccination were explored. After screening and due exclusions, 198 studies were included for the final review. Patients with SLE have a greater risk of acquiring COVID-19 (0.6–22%) and related hospitalization (30%), severe disease (13.5%), and death (6.5%) than the general population. Older age, male gender, comorbidities, moderate or high disease activity, and glucocorticoid, rituximab, and cyclophosphamide use are associated with unfavorable outcomes, whereas methotrexate and belimumab use showed no association with outcomes. COVID-19 vaccines are safe in SLE with minimal risk of severe flares (< 2%). Vaccine efficacy is negatively associated with glucocorticoids. The overall attitude of patients towards vaccination is positive (54–90%). The pandemic has negatively affected access to medical care, hospitalizations, procurement of drugs, employment, and the mental health of patients which need to be addressed as part of holistic care in SLE. Key Points • Lupus patients are at a greater risk of acquiring COVID-19, related hospitalization, severe disease, and death than the general population. • COVID-19 vaccines are relatively safe for lupus patients with minimal risk of severe flares. • Lupus patients’ attitude towards COVID-19 vaccination is predominantly positive.

show abstract

“…Entre os principais sinais e sintomas a febre estava presente na maioria dos casos, seguidos de tosse, falta de ar, diarreia e vômito (ANG et al, 2021;AL YAZIDI et al, 2021;GRAFF et al, 2021;MADANI et al, 2021;PARCHA et al, 2021;SHAHBAZNEJAD et al, 2021;CLEMENTE et al, 2021;MANNHEIM et al, 2020;DESAI et al, 2020;NATHAN et al, 2020;ZACHARIAH et al, 2020;ZHENG F et al, 2020;.…”

Section: Discussionunclassified

“…Entretanto, alguns estudos não apontam os resultados dos exames para justificar a oxigenioterapia. Nesses casos os sinais clínicos como dispneia, esforço respiratório e exames laboratoriais alterados justificaram algumas intervenções (AL YAZIDI et al, 2021;BARONIO et al, 2021;BELLINO et al, 2021;BUNDLE et al, 2021;KOMAPNIYETS et al, 2021;MOREIRA et al, 2021;RABHA et al, 2021;SENA et al, 2021;GRAFF et al, 2021;PARCHA et al, 2021;ROJAS et al, 2021;OZENEN et al, 2021;SHAHBAZNEJAD et al, 2021;CLEMENTE et al, 2021;MANNHEIM et al, 2020;DESAI et al, 2020;NATHAN et al, 2020;HILESHEIM et al, 2020).…”

Section: Base De Dados Estratégia De Buscaunclassified

A Violência No Contexto Do Isolamento Social Da Pandemia Da Covid-19 No Estado Do Amazonas

Oliveira¹,

Duarte²,

Bentes³

et al. 2022

Covid-19: O Maior Desafio Do Século XXI

View full text Add to dashboard Cite

Direitos para esta edição cedidos à Atena Editora pelos autores. Open access publication by Atena Editora Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0). O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação com base em critérios de neutralidade e imparcialidade acadêmica.A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação, evitando plágio, dados ou resultados fraudulentos e impedindo que interesses financeiros comprometam os padrões éticos da publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.

show abstract

Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases

Cited by 20 publications

References 23 publications

Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases—cross-sectional study from a reference centre in Spain

Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases—cross-sectional study from a reference centre in Spain

Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management

A Violência No Contexto Do Isolamento Social Da Pandemia Da Covid-19 No Estado Do Amazonas

Contact Info

Product

Resources

About